Healthcare ETFs are hitting one-year highs because the sector is benefiting from a solid combination of improving earnings visibility, attractive relative valuations, and a rotation out of overcrowded AI\/tech trades into defensive growth. <\/p>\n
After years of underperformance, the sector has brightened up over the past one month. State Street Health Care Select Sector SPDR ETF <\/strong>XLV has surged 6.6% over the past month compared with 3.4% gains seen in State Street SPDR S&P 500 ETF Trust<\/strong> SPY. <\/p>\n Inside the Rally Earnings Acceleration <\/p>\n S&P 500 healthcare companies are expected to deliver double-digit earnings growth from Q4 2026 through 2027, a sharp turnaround after years of underperformance. This forward profitability upgrade is drawing fresh institutional flows, per Reuters. <\/p>\n The medical sector is likely to record a 1.7% uptick in earnings on 5.3% higher revenues. The sector is expected to log a 21.2% increase in earnings on 2.2% higher revenues, Zacks Sector and Market Earnings Trends, issued on Aug. 12, 2026. Historically, the sector reported a 12.6% rise in earnings on 10.6% higher revenues in 2025. <\/p>\n Improving Margins <\/p>\n After lagging in early 2026, healthcare now offers “durable growth, technology-like profitability, attractive valuation and diversification benefits” compared with the AI-heavy market leadership, per J.P. Morgan, as quoted on Reuters. <\/p>\n While the healthcare sector has lagged the red-hot technology sector on the margins front in 2025 and 2026, the sector is expected to report a 1.40% margin expansion in 2027 versus the technology sector’s expected 0.02% margin expansion, per Zacks Earnings Trends. <\/p>\n Pharma Stocks Enter 2026 H2 On Firmer Footing <\/p>\n Large pharmaceutical companies are entering the second half of 2026 on much firmer footing than they were a year ago. Concerns over tariffs and U.S. drug pricing policies have eased considerably, allowing investors to shift their focus back to company fundamentals. <\/p>\n Meanwhile, despite continued leadership changes at the Food and Drug Administration (FDA), drug approvals have remained healthy, with early indications pointing to a more flexible regulatory environment, per a Janus Henderson report. <\/p>\n Solid Dealmaking <\/p>\n M&A activity is surging. M&A value in the sector has touched nearly $284 billion this year, according to Dealogic, approaching 2025’s total of $306 billion and topping every other year since 2021, as quoted on Reuters. <\/p>\n A\u00a0recent media report\u00a0indicated that AstraZeneca (AZN) and Bristol-Myers Squibb\u00a0(BMY) held talks about a possible merger, which could create one of the \u200cworld’s largest pharma companies with a combined value of nearly $400 billion, the same Reuters article noted. <\/p>\n Story Continues <\/p>\n Rising Hedge Funds Investments <\/p>\n Hedge fund bets in favor of healthcare stocks recently neared a five-year high, per a Goldman Sachs note, as cash-rich speculators believe AI-driven breakthroughs and favorable financing conditions will help the sector meaningfully, as quoted on Reuters. <\/p>\n Specialized healthcare hedge funds posted returns of nearly 40% between August 2025 and April 2026, compared with 17% returns for generalist stock-trading hedge funds over the same time frame, per Goldman Sachs, as mentioned in the same Reuters article. <\/p>\n More hedge funds are focusing exclusively on healthcare this year, with the sector accounting for 24% of new fund launches\u2014the highest share since at least 2009, the bank added, as quoted on Reuters. <\/p>\n Fast FDA Approvals <\/p>\n The FDA has accelerated its approval process, with the annual number of new drug approvals in 2025 reaching its highest level since 2020, according to Goldman Sachs, citing data through the end of last year, per the same Reuters article. <\/p>\n Defensive Rotation <\/p>\n In volatile periods and ahead of U.S. midterm elections, investors historically rotate into defensive sectors. Moreover, with many portfolios still concentrated in tech\/AI, where valuation concerns persist, healthcare’s lower correlation provides a hedge against volatile days. <\/p>\n ETFs in Focus <\/p>\n Against this backdrop, below we highlight a few healthcare ETFs that have hit a 52-week high lately. <\/p>\n S&P Pharmaceuticals SPDR <\/strong>XPH <\/p>\n The underlying S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. No stock makes up more than 3.71% of the fund. The $519.1-million-fund charges 35 bps in fees. <\/p>\n U.S. Pharmaceuticals iShares ETF <\/strong>IHE <\/p>\n The underlying index of the fund includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is heavy on Eli Lilly and J&J. The $1.63-billion-fund charges 38 bps in fees. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n S&P 500 Healthcare Sector SPDR <\/strong>XLV <\/p>\n The underlying Health Care Select Sector Index includes companies from the following industries: pharmaceuticals; health care providers & services; health care equipment & supplies; biotechnology; life sciences tools & services; and health care technology. This fund is also heavy on Eli Lilly and J&J. The $43.8-billion-fund charges 8 bps in fees. \u00a0\u00a0\u00a0\u00a0 <\/p>\n Invesco Pharmaceuticals ETF <\/strong>PJP <\/p>\n The underlying Dynamic Pharmaceutical Intellidex Index is comprised of stocks of U.S. pharmaceutical companies. $512-million-fund charges 57 bps in fees. No stock makes up more than 5.58% of the fund. <\/p>\n Vaneck Biotech ETF <\/strong>BBH <\/p>\n The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. The $428.8-million-fund charges 35 bps in fees. <\/p>\n Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a> <\/p>\n State Street SPDR S&P 500 ETF Trust (SPY): ETF Research Reports<\/a> <\/p>\n State Street Health Care Select Sector SPDR ETF ETF (XLV): ETF Research Reports<\/a> <\/p>\n Invesco Pharmaceuticals ETF (PJP): ETF Research Reports<\/a> <\/p>\n iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports<\/a> <\/p>\n State Street SPDR S&P Pharmaceuticals ETF (XPH): ETF Research Reports<\/a> <\/p>\n VanEck Biotech ETF (BBH): ETF Research Reports<\/a> <\/p>\n This article originally published on Zacks Investment Research (zacks.com).<\/a> <\/p>\n